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Background and aim: Real-time endobronchial ultrasound-guided transbronchial needle aspi-
ration (EBUS-TBNA) is a minimally invasive technique for diagnosis of mediastinal lymphade-
nopathy. Although most studies have reported the utility of EBUS-TBNA in malignancy, its
use has been extended to benign conditions including sarcoidosis. Herein, we perform
a systematic review and meta-analysis of studies reporting the diagnostic yield and safety of
EBUS-TBNA in sarcoidosis.
Methods: We searched the PubMed and EmBase databases for relevant studies published from
2004 to 2011, and included studies that have reported the diagnostic yield of EBUS-TBNA in
sarcoidosis. The quality of studies was assessed using the QualSyst tool. We calculated the
proportions with 95% confidence interval (CI) to assess the diagnostic yield of EBUS-TBNA in
individual studies and then pooled the results using a random effects model. Heterogeneity
was assessed using the I2 and Cochran-Q tests while publication bias was assessed using both
graphical and statistical methods.
Results: Our search yielded 15 studies (553 patients of sarcoidosis). The diagnostic yield
of EBUS-TBNA ranged from 54 to 93% with the pooled diagnostic accuracy being 79% (95% CI,
71e86%) by the random effects model. The yield was not statistically different in studies
employing on-site cytological evaluation (80.1%) vs. those without (81.3%). However, the
diagnostic yield was significantly higher in prospective studies (83.9%) vs. the retrospective
studies (74.3%). Only five minor complications were reported in 553 patients. There was
evidence of heterogeneity and publication bias.
Conclusions: EBUS-TBNA is a safe and efficacious procedure in the diagnosis of sarcoidosis, and
should be routinely employed wherever available.
ª 2012 Elsevier Ltd. All rights reserved.t of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Sector-12,
72 2756823; fax: þ91 172 2748215.
il.com (D. Gupta).
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Sarcoidosis is a multisystem granulomatous disorder of
unknown etiology that commonly presents with bilateral
hilar adenopathy, pulmonary infiltrates, ocular and skin
lesions. The diagnosis is established in presence of
compatible clinicoradiographic findings and histologic
evidence of noncaseating epithelioid cell granulomas after
exclusion of other known causes for granulomatous
inflammation.1 As the lung and mediastinal lymph nodes are
most often affected in sarcoidosis, bronchoscopic tech-
niques are often employed for demonstration of non-
caseating granulomas. Bronchoscopic lung biopsy (BLB),
endobronchial biopsy (EBB) and transbronchial needle
aspiration (TBNA) are currently the most commonly used
methods for demonstration of granuloma in sarcoidosis.
Endobronchial ultrasound-guided TBNA (EBUS-TBNA) is
a minimally invasive technique for sampling the hilar/
mediastinal lymph nodes, and can improve the diagnostic
yield by direct visualization of lymph node beyond the
tracheobronchial wall thereby allowing real-time sampling
of the lymph nodes.2
Krasnik et al. first reported the utility of convex probe
EBUS-TBNA in sampling mediastinal nodes in 2003.3 With
time, the diagnostic yield of EBUS-TBNA has been further
enhanced by rapid on-site cytological evaluation (ROSE),
increasing the number of lymph nodes sampled, increase in
the number of aspirates taken per node, and use of a larger
bore 21G needle. Although EBUS-TBNA was primarily
intended for minimally invasive staging of bronchogenic
carcinoma, its use has been extended in diagnosis of
lymphoma and benign conditions like tuberculosis and
sarcoidosis.4e6 Several systematic reviews and meta-
analyses have reported the diagnostic performance of
EBUS-TBNA but most of these reviews have primarily
focused on patients with malignancy.7e11
Sarcoidosis is a common pulmonary disorder worldwide.
Demonstration of noncaseating granulomas and exclusion of
other causes of granulomatous inflammation is essential
particularly in countries with high prevalence of tubercu-
losis. We had previously reported the diagnostic yield of
BLB and the additive yield of EBB in patients with sarcoid-
osis.12 We have also recently reported the diagnostic yield
of TBNA in patients with mediastinal lymphadenopathy of
diverse etiologies including sarcoidosis.13 In this study, we
perform a systematic review and meta-analysis to define
the diagnostic efficacy and safety of convex probe EBUS-
TBNA in patients with sarcoidosis.
Material and methods
Search strategy
We first searched the literature for available systematic
review that had reported the diagnostic efficacy of EBUS-
TBNA in sarcoidosis. No systematic reviews were found. All
the authors independently searched two computer data-
bases PubMed and EmBase for relevant studies published
from 2004 to 2011 describing the diagnostic value of EBUS-
TBNA in patients with sarcoidosis using the following search
terms: (“ebus”OR“ebus tbna”OR“tbna”OR“endobronchialultrasound” OR “endobronchial ultrasonography” OR
“endobronchial ultrasound-guided” OR “endoscopic ultra-
sound” OR “transbronchial needle aspiration”) AND
sarcoidosis; and, (“ebus” OR “endobronchial ultrasound” OR
“endobronchial ultrasonography” OR “endobronchial ultra-
sound-guided” OR “endoscopic ultrasound”) AND (“tbna” OR
“transbronchial needle aspiration”). We reviewed the
reference lists of primary studies, reviews, and editorials. In
addition, we reviewed our personal files. We excluded the
following studies: (a) abstracts, editorials, reviews and case
reports; (b) studies describing diagnostic accuracyof TBNAor
endoscopic ultrasound-guided fine needle aspiration (EUS-
FNA) or radial probe EBUS-TBNA in sarcoidosis; (c) studies
describing EBUS-TBNA in 10 patients with sarcoidosis; (d)
studies in which the denominator number i.e. number of
patients with final diagnosis of sarcoidosis (granulomas on
EBUS-TBNA or demonstration of granulomas from any site by
any methodology AND a clinical picture deemed by the
investigator to be compatible with sarcoidosis) was not
reported. The criteria for conclusive diagnosis by EBUS-TBNA
in sarcoidosis was lymph node aspirates showing epithelioid,
noncaseating granulomas without necrosis OR epithelioid
and giant cells AND absence of identifiable malignancy,
lymphoma, or infection (i.e. tuberculosis or fungal disease).
Initial review of studies
The initial database created from the electronic searches
was compiled and all duplicate citations were eliminated.
Two reviewers (RA and AS) screened these citations,
without blinding, by title and abstract review to capture
the relevant studies. Any disagreement was resolved by
discussion between the authors. This database was then
screened again to include only primary articles, and the full
text of each citation was obtained and reviewed. Studies
were eligible for inclusion if they reported the diagnostic
yield of convex probe EBUS-TBNA in patients with clinical
suspicion of sarcoidosis.
Data abstraction
Data was recorded on a standard data extraction form. The
following items were extracted: (a) publication details
(title; authors; and other citation details) including the
geographic location of the study; (b) type of study
(prospective or retrospective); (c) stage of sarcoidosis and
lymph node size on CT chest; (d) type of sedation used,
diameter of EBUS-TBNA needle, stations sampled, size of
lymph node on EBUS, number of lymph node aspirated and/
or passes made through EBUS, availability of on-site
cytology; (e) diagnostic yield of EBUS-TBNA in sarcoidosis
wherein the numerator was the diagnosis of sarcoidosis
with EBUS-TBNA, and the denominator was number of
patients with confirmed sarcoidosis; and, (f) complications
associated with the procedure.
Assessment of study quality
The quality and validity of each article included in this
meta-analysis was assessed using the QualSyst tool for
qualitative studies.14 This tool consists of 10 questions with
Systematic review & meta-analysis 885score from 0 to 2 with the maximum total score being 20.
Each study was independently evaluated by two authors
(RA, AS) for the stated criteria. Weighted Cohen’s kappa (k)
co-efficient was used to determine the inter-observer
agreement for selection of studies.
Statistical analysis
The statistical software package (StatsDirect, version 2.7.8
for MS Windows; StatsDirect Ltd; Cheshire, UK [http://
www.statsdirect.com]) was used to perform all the statis-
tical analysis.
Determination of the pooled effect
We calculated the diagnostic yield of EBUS-TBNA by calcu-
lating proportion with 95% confidence intervals (CI) for each
study and then pooled the data to derive a pooled proportion
with 95%CI. For the purpose of proportionmeta-analysis, the
proportions were first turned into a quantity (the Freeman-
Tukey variant of the arcsine square root transformed
proportion) suitable for the random effects summary.15,16
The pooled proportion was calculated as the back-
transform of the weighted mean of the transformed
proportions, using DerSimonian weights for the random
effects model17 in the presence of significant heterogeneity.
Assessment of heterogeneity
The impact of heterogeneity on the pooled estimates of the
outcome was assessed using the Cochran Q statistic and I2
test (measures the extent of inconsistency among the
results of the studies). An I2 value 50% indicates signifi-
cant heterogeneity.18 As the Cochran Q test has a low
sensitivity for detecting heterogeneity, a p value <0.1 was
considered to be significant for the presence of statistical
heterogeneity.19
Sensitivity/subgroup analysis
We planned sensitivity analysis a priori by using subgroup
analysis of prospective vs. retrospective studies due to the
limitations associated with retrospective studies, and the
occurrence of errors associated with the retrieval of
information retrospectively from databases. A subgroup
analysis was also planned by partitioning the studies based
on the utilization of ROSE for histological diagnosis.
Assessment of publication bias
The presence of publication bias was evaluated using the
Begg’s funnel plot,20 which is a measure of the proportion
(in the X-axis) against the standard error of the proportion
(in the Y-axis). Each open circle represents an individual
study in the meta-analysis. The line in the center indicates
the pooled proportion and the other two lines indicate the
95% CI. The proportion estimates from smaller studies are
expected to be scattered above and below the summary
estimate, producing a triangular or funnel shape, if there is
no publication bias.Publication bias was also investigated using three
statistical tests: (a.) Egger test: detects asymmetry of the
funnel plot21; (b.) Harbord’s test: similar to Egger’s test but
uses a modified linear regression method22; and, (c.) Begg
and Mazumdar’s test: tests the interdependence of vari-
ance and effect size using a rank correlation method.23
An Institutional review board clearance was not required
for this study as this was a meta-analysis of published
studies.Results
Our initial database search retrieved a total of 504 citations
(Fig. 1) of which 15 studies finally met our inclusion
criteria.24e38 Of these, nine studies were pro-
spective24e26,29,31e34,37 and six were retrospective (Table 1).
These 15 studies were published from across the globe and
included 553 confirmed patients of sarcoidosis. Eight studies
included stage I and II patients of sarcoidosis,25,26,28e31,37,38
two studies24,33 included all stages of sarcoidosis while the
stage was not reported in five studies (Table 1). The proce-
dure was performed under conscious sedation without any
artificial airway in 12 studies (Table 2). Two studies used
conscious sedation with either endotracheal tube or laryn-
geal mask25,38 while one study used general anesthesia with
laryngeal mask.30 Majority of the studies had sampled the
paratracheal, subcarinal, hilar and interlobar nodes, and all
the studies had used the 22G dedicated EBUS-TBNA needle.
The lymph node size on CT and EBUS, the number of lymph
nodes aspirated and the number of aspirates per patient is
shown in Table 2. Five studies employed additional rapid on-
site cytology,24,26,28,36,38 and two studies employed liquid-
based cytological technique for diagnosis.30,35 The quality
of studies was generally good (Table 3) with themedian (IQR)
score being 18 (18e19). The inter-observer agreement for
scoring the quality of studies was good. (Cohen’s kZ 0.78).
The diagnostic yield of EBUS-TBNA in sarcoidosis ranged
from 54 to 93% with the pooled accuracy being 79% (95% CI,
71e86%) by the random effects model (Fig. 2). The yield
was not statistically different (p Z 0.66) in studies
employing on-site cytological evaluation (165/206; 80.1%)
vs. those without (282/347; 81.3%). The diagnostic yield
was higher in prospective studies (314/374; 83.9%)
compared to retrospective studies (133/179; 74.3%), and
this difference was statistically significant (p Z 0.006).
Only five minor complications (minimal pneumothorax,
minor bleeding, airway edema/hypoxemia [n Z 2], pro-
longed cough) were reported in 532 patients.24,34,36,37
There was clinical heterogeneity reflected in the nature
of the study (prospective vs. retrospective), inclusion of
patients with various stages, variation in the number of
passes or lymph nodes sampled, utilization of on-site
cytology and use of different cytological techniques
(Tables 1and 2). There was also significant statistical
heterogeneity (I2 79.7; [95% CI, 65.9e86.3%]; Cochran Q
statistic 69.03, p < 0.0001). There was evidence of publi-
cation bias on visual examination of the funnel plot (Fig. 3).
There was also evidence of publication bias on some (Egger:
biasZ 3.22, p < 0.0008) but not all statistical tests (Begg-
Mazumdar: Kendall’s tau Z 0.371, p Z 0.05; Harbord-
Egger: bias Z 2.89, p Z 0.19).
Figure 1 Citation selection process for the systematic review.
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A subgroup analysis was performed and only prospective
studies were included after which there was no significant
change in heterogeneity (I2 84%; Cochran Q statistic 50.1
[p < 0.0001]) or publication bias (Egger: bias Z 3.01,
p < 0.02; Begg-Mazumdar: Kendall’s tau Z 0.33,
p Z 0.18; Harbord-Egger: bias Z 2.81, p Z 0.38). Simi-
larly there was no change in heterogeneity (I2 79.4%;
Cochran Q statistic 19.4 [p Z 0.0007]) and publication bias(Egger: biasZ 5.46, pZ 0.01; Begg-Mazumdar: Kendall’s
tau Z 1, p < 0.0001; Harbord-Egger: bias Z 13.56,
p Z 0.03) after inclusion of studies employing ROSE.Discussion
The result of this meta-analysis suggests an excellent
overall diagnostic yield (79%) of EBUS-TBNA in sarcoidosis
suggesting that this technique should be routinely
Table 1 Demographic characteristics of patients in studies reporting the performance of EBUS-TBNA in sarcoidosis.
Author (year) Geographic locale Type of study Age (in years) Patients included Stage of sarcoidosis
Garwood (2007)24 USA Prospective 19e79 (range) 48 0e4
Oki (2007)25 Japan Prospective 27e73 (range) 14 1,2
Wong (2007)26 Germany, Japan Prospective 45 (mean) 61 1,2
Szlubowski (2008)27 Poland Retrospective NA 21 NA
Nakajima (2009)28 Japan Retrospective 48.2 (median) 32 1,2
Tremblay (2009)29 Canada Prospective 39.5 (mean) 24 1,2
Eckardt (2010)30 Denmark Retrospective 53 (median) 43 1,2
Kim (2010)31 Korea Prospective 45.1 (mean) 25 1,2
Tian (2010)32 China Prospective 52.3 (mean, all patients)a 16 NA
Tournoy (2010)33 Belgium Prospective 43 (median, all patients)a 54 0e4
Cetinkaya (2011)34 Turkey Prospective 50.2 (mean, all patients)a 105 NA
Delattre (2011)35 France Retrospective 21e79 (range) 18 NA
Jernlas (2011)36 Sweden Retrospective 63 (mean, all patients)a 28 NA
Navani (2011)37 United kingdom Prospective 19e68 (range) 27 1,2
Plit (2011)38 Australia Retrospective 42 (mean) 37 1,2
NA e not available.
a All patients of mediastinal lymphadenopathy including the subgroup of patients with sarcoidosis.
Systematic review & meta-analysis 887employed in diagnosis of sarcoidosis wherever available.
The analysis includes good quality studies involving more
than 550 confirmed predominantly stage I and II patients of
sarcoidosis. The lower paratracheal and subcarinal lymph
nodes (stations 4 and 7) were the most frequently accessed
with a very low rate of complications.Table 2 Details of the EBUS-TBNA procedure in various studies
Author (year) Node size
on CT (mm)
Sedation Statio
exami
Garwood (2007)24 >10 mm Conscious sedation 4,7,10
Oki (2007)25 >10 mm Conscious sedation
via endotracheal tube
4,7,10
Wong (2007)26 >10 mm Conscious sedation 2,4,7,
Szlubowski (2008)27 >10 mm Conscious sedation 2,3,4,
Nakajima (2009)28 >10 mm Conscious sedation 4,7,10
Tremblay (2009)29 >10 mm Conscious sedation As app
Eckardt (2010)30 NA GA via LMA 2,3,4,
Kim (2010)31 NA Conscious sedation 4,7,10
Tian (2010)32 NA Conscious sedation 2,3,4,
Tournoy (2010)33 >10 mm Conscious sedation 4,7,10
Cetinkaya (2011)34 >10 mm Conscious sedation 2,4,7,
Delattre (2011)35 NA Conscious sedation As app
Jernlas (2011)36 >10 mm Conscious sedation As app
Navani (2011)37 >10 mm Conscious sedation 4,7,10
Plit (2011)38 NA Conscious sedation
via LMA
4,7
CT e computed tomography.
GA e general anesthesia.
LMA e laryngeal mask airway.
NA e not available.The diagnosis of sarcoidosis is incomplete without the
demonstration of noncaseating granuloma.1 Serum angio-
tensin converting enzyme levels are often elevated in
sarcoidosis, but are non-specific as several common condi-
tions like tuberculosis and diabetes mellitus also show
similar elevation.39,40 Gallium-67 scan findings of panda orreporting the performance of EBUS-TBNA in sarcoidosis.
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888 R. Agarwal et al.lambda sign can support the diagnosis but are seen only in
limited patients and cannot replace histology.41,42 Over the
last two decades, bronchoscopic techniques are most often
used to confirm the diagnosis of sarcoidosis. The bron-
choalveolar lavage fluid lymphocyte marker specifically the
CD4/CD8 ratio (>3.5) has been used as an adjunct to
support the diagnosis of sarcoidosis. Although a high CD4/
CD8 ratio supports the diagnosis of sarcoidosis, its distri-
bution is variable and is not a substitute for histology.43 BLB
is the most commonly performed procedure in establishing
a diagnosis of sarcoidosis.1 However, the yield of BLB
depends not only on the experience of operator but also on
the stage of sarcoidosis (higher in stage II than I),44 and the
number of biopsies obtained (optimal at 8e10).45,46 The
diagnostic yield of BLB ranges between 40 and 90%,45,47 and
carries a risk of pneumothorax (2%) and hemoptysis (5%).48
EBB can add to the diagnostic yield of BLB especially if the
mucosa appears abnormal, although 30% of normal
appearing mucosa can also show evidence of granuloma on
histology.12,49 Conventional TBNA alone has a variable
success ranging from 42 to 76%, with a higher yield in stage I
disease.48,50,51 However, the steep learning curve and
variable yield has lured few pulmonologists to adopt TBNA
as a routine procedure.52,53 Combination of modalities such
as conventional TBNA, EBB and TBLB can increase the yield
to 70e90%,13,48,54 but is often associated with increase in
duration of procedure and complications. EUS-FNA has
shown promise in diagnosis of sarcoidosis with studies
reporting sensitivity of 89e100% and specificity of
94e96%.55e57 The limitations of EUS-FNA include inability to
perform additional procedures like BLB or EBB at the same
time and difficulty in accessing paratracheal, hilar and
interlobar (stations 2, 4, 10, 11) especially on the right side
given the fact that these are the nodes that are usually
enlarged in sarcoidosis.
Mediastinoscopy is currently the ‘gold’ standard for
sampling mediastinal lymph nodes.58 However, the proce-
dure is not routinely available at all centers, and is asso-
ciated with major morbidity/mortality ranging from 1.4 to
2.3% depending on the experience of the operator.59 The
diagnostic yield ranges between 82 and 97% for undiag-
nosed mediastinal adenopathy,60e62 with the major caveat
being that not all mediastinal nodes can be accessed with
this technique. Mediastinoscopy however is the final resort
if all other techniques fail. There is scarce evidence
regarding computed tomography (CT)-guided transthoracic
needle aspiration (TTNA) and/or biopsy of the mediastinal
nodes for diagnosis of sarcoidosis. Moreover, there is a high
risk of complications especially pneumothorax with CT-
guided TTNA. Klein et al. recently reported their 10 year
single center experience in 41 patients of sarcoidosis. The
diagnostic yield was 78% with cytology and 96% with core
biopsy, however they also reported pneumothorax in 22% of
patients.63
Most studies included in this meta-analysis have repor-
ted a diagnostic yield around 80% for EBUS-TBNA in
sarcoidosis.24e27,29,31,34,35,37,38 According to the results of
this study, the diagnostic yield of EBUS-TBNA surpasses
every other bronchoscopic investigation in isolation. More-
over, combining EBUS-TBNA with BLB and EBB would
significantly add to the diagnostic yield, and would be able
to achieve a diagnosis in majority of the cases. Of the
Figure 2 Diagnostic yield of EBUS-TBNA in patients with sarcoidosis (random effects model). The yield in individual studies is
represented by a square (percentage) through which runs a horizontal line (95% confidence interval). The diamond at the bottom
represents the pooled prevalence from the studies (79% [95% CI, 71e86%]).
Systematic review & meta-analysis 889studies reporting a lower yield, Jernlas et al. and Tian et al.
have attributed their results to learning curve, diversity of
diagnosis and referral bias.32,36 Eckardt et al. and Tournoy
et al. included only patients who remained undiagnosed
despite usual bronchoscopic interventions and thus a subset
of patients where the granuloma load was likely to haveFigure 3 Funnel plot comparing proportion vs. the standard
error of proportion. Open circles represent trials included in
the meta-analysis. The line in the center indicates the
summary proportion. The other lines represent the 95% confi-
dence intervals. Asymmetry about the pooled line is consistent
with the presence of publication bias.been less than usual.30,33 Nakajima et al. reported a diag-
nostic yield on 91.4% however they had used the presence
of epithelioid cells alone as criteria for diagnosis of sarcoid
in 10 of the 32 cases thereby decreasing their actual yield
to 69%.28
Finally, the meta-analysis has certain limitations. There
was presence of significant clinical and statistical hetero-
geneity in the studies evaluated although we used the
random effects model for minimizing the effects of
heterogeneity.18 We also performed a sensitivity analyses
to investigate the cause of heterogeneity by including only
studies of prospective nature and those employing ROSE.
The sensitivity analysis did not explain the statistical
heterogeneity suggesting that other factors contributed to
heterogeneity. The meta-analysis included studies from
various centers with operators having differing levels of
expertise in performing EBUS-TBNA which we believe is the
prime contributor of heterogeneity in this analysis.
Heterogeneity is the presence of variability among studies
included in a systematic review and can be broadly classi-
fied as clinical heterogeneity (variability in the partici-
pants, interventions, and outcomes) or methodological
heterogeneity (variations in trial design and quality) or
statistical heterogeneity (variability in the treatment
effects being evaluated in different trials). In fact, one can
argue that in a meta-analysis heterogeneity is inevitable
whether or not statistical tests detect them or not. The
strength of this meta-analysis is the sample size (almost 550
patients with sarcoidosis), detailed extraction of data from
890 R. Agarwal et al.individual studies and the robust statistical methods
applied in the analysis. Future studies on EBUS-TBNA in
sarcoidosis should employ a uniform methodology with
regards to the number of lymph nodes aspirated (at least
two lymph node stations), the number of passes per lymph
node (at least two passes per lymph node) and the use of
consistent liquid-based cytology protocol.
Conclusions
In conclusion, the result of this study suggests a high
diagnostic yield and safety of EBUS-TBNA in sarcoidosis,
indicating that EBUS-TBNA should be routinely employed in
the diagnosis of sarcoidosis wherever available.
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